Status:
COMPLETED
Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
Lead Sponsor:
Mclean Hospital
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, doubl...
Detailed Description
Previous studies examining the effect of omega-3 fatty acids on bipolar depression have had mixed results. Some studies have found that omega-3 fatty acids have a positive effect on bipolar depression...
Eligibility Criteria
Inclusion
- bipolar disorder
- mood episode within past year
- stable medication regimen
Exclusion
- primary psychiatric disorder other than bipolar disorder
- significant suicide or homicide risk
- unstable medical conditions
- current or planned pregnancy
- lactose intolerance
- medications affecting lipid absorption or metabolism
- clozapine treatment
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00854737
Start Date
July 1 2004
End Date
July 1 2010
Last Update
April 20 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
2
Jersey Shore University Medical Center
Neptune City, New Jersey, United States, 07753